BioXcel Therapeutics
BTAI
36 hedge funds and large institutions have $32.6M invested in BioXcel Therapeutics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 2 closing their positions.
800% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
80% more funds holding
Funds holding: 20 → 36 (+16)
31% more capital invested
Capital invested by funds: $24.9M → $32.6M (+$7.64M)
0.19% more ownership
Funds ownership: 1% → 1.2% (+0.19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$3.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$857K |
| 3 |
State Street
Boston,
Massachusetts
|
+$679K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$372K |
| 5 |
Squarepoint
New York
|
+$340K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.42M |
| 2 |
Creative Planning
Overland Park,
Kansas
|
-$154K |
| 3 |
Millennium Management
New York
|
-$127K |
| 4 |
Morgan Stanley
New York
|
-$25.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$9.49K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
26
STRS Ohio
Columbus,
Ohio
| $17K | +$16.9K | +100 | New |
|
|
27
Bank of America
Charlotte,
North Carolina
| $14K | -$9.49K | -56 | -43% |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| $11K | +$5.42K | +32 | +103% |
|
29
Legal & General Group
London,
United Kingdom
| $11K | +$10.7K | +63 | New |
|
|
AIP
30
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | +$5.59K | +33 | New |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $4K | +$4.07K | +24 | New |
|
32
Wells Fargo
San Francisco,
California
| $3K | -$508 | -3 | -12% |
|
|
GWM
33
Geneos Wealth Management
Englewood,
Colorado
| $2K | – | – | – |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$1.02K | +6 | New |
|
35
BNP Paribas Financial Markets
Paris,
France
| $175 | +$169 | +1 | New |
|
|
36
Millennium Management
New York
| – | -$127K | -804 | Closed |
|
|
37
Morgan Stanley
New York
| – | -$25.6K | -151 | -98% |
|
38
Nordea Investment Management
Stockholm,
Sweden
| – | -$1K | -6 | Closed |
|
BTAI Hedge Fund Activity: Q2 2019 in Review
36 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q2 2019, worth a combined $32.6M — up 31% from $24.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BTAI positions and 2 closed out — a net gain of 16 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, adding an estimated $3.02M. The largest seller was Fidelity Investments, cutting an estimated $1.42M.
- 36 institutional investors held BioXcel Therapeutics (BTAI) as of Q2 2019, up from 20 in Q1 2019.
- Funds reported $32.6M of BioXcel Therapeutics stock for Q2 2019, up 31% quarter-over-quarter.
- 18 funds opened new BioXcel Therapeutics positions in Q2 2019 and 2 closed out, a net change of +16 holders.
- The largest BioXcel Therapeutics buyer in Q2 2019 was BlackRock, an estimated $3.02M added.
- The largest BioXcel Therapeutics seller in Q2 2019 was Fidelity Investments, an estimated $1.42M sold.
Based on aggregated 13F filings for Q2 2019.